LongBio Pharma (Suzhou) Company Description

LongBio Pharma (Suzhou) Co., Ltd. engages in discovery and development of biopharmaceuticals that targets allergic and autoimmune diseases in the People's Republic of China and Hong Kong.

The company's products includes LP-003, an anti-IgE antibody with novel sequencing; LP-005, bi-functional antibody fusion protein; LP-00A, a bi-functional antibody for allergic diseases; LP-00C, a bi-functional antibody or fusion protein for B-cell mediated autoimmune diseases; and LP-00D, a bi-functional antibody or fusion protein complement inhibitor for specific tissues,organs and indications.

The company was founded in 2020 and is based in Changshu, China.

LongBio Pharma (Suzhou) Co., Ltd.

Country	China
Founded	2020
Industry	Biotechnology
Sector	Healthcare
Employees	85
CEO	Heng Liu

Contact Details

Address: Building F, Area A Changshu, 215500 China
Phone	86 21 5837 2970
Website	longbio.com

Stock Details

Ticker Symbol	1779
Exchange	Hong Kong Stock Exchange
Fiscal Year	January - December
Reporting Currency	CNY
ISIN Number	CNE100007NF2
SIC Code	2836

Key Executives

Name	Position
Heng Liu	Chief Executive Officer